Stereotactic body radiotherapy takes on Lung Oligometastases: Latest breakthroughs

Abstract

Lung oligometastases represent an intermediate state of cancer dissemination between localized and widespread metastases. Stereotactic body radiation therapy (SBRT) has emerged as an effective treatment option, with an efficacy comparable to that of surgical resection. This review aimed to provide a comprehensive summary of the latest advancements and controversial issues regarding SBRT for lung oligometastases. It focuses on four crucial perspectives: efficacy of SBRT, optimal patient selection criteria, technological innovations, and synergistic effects of SBRT combined with systemic therapy. Relevant clinical trials investigating SBRT for lung oligometastases have been conducted, with median 1- and 5-year local control rates of 90% and 79%, respectively. The origin of the primary tumor, size and number of lesions, and biomarker profiles were highlighted as pivotal considerations in patient selection. The precise dose delivery was enhanced using robotic SBRT and optimized dose fractionation schemes. Evidence suggests that dose escalation above 100 Gy biologically effective dose may improve tumor control. Combined immunotherapy and SBRT have demonstrated synergistic effects in prolonging progression-free survival and overall survival. This review provides valuable insights into the precise treatment of oligometastatic lung diseases using SBRT. Further multicenter randomized trials are warranted to develop definitive patient selection criteria and optimize the integration with systemic therapies.

Keywords

lung oligometastases / stereotactic ablative radiotherapy / stereotactic body radiotherapy

References

[1] HellmanS, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8.

[2] MayingerM, Kotecha R, SahgalA, et al. Stereotactic Body Radiotherapy for Lung Oligo-metastases: Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines. Lung Cancer. 2023;182:107284

[3] JasperK, StilesB, McDonaldF, Palma DA. Practical Management of Oligometastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(6):635-641.

[4] DasA, Giuliani M, BezjakA. Radiotherapy for Lung Metastases: Conventional to Stereotactic Body Radiation Therapy. Semin Radiat Oncol. 2023;33(2):172-180.

[5] FodorA, MoriM, TummineriR, et al. CT radiomic predictors of local relapse after SBRT for lung oligometastases from colorectal cancer: a single institute pilot study. Strahlenther Onkol. 2023;199(5):477-484.

[6] Ramos-PrudencioR, Lozano-Ruiz F, Rodríguez-LagunaA, Poitevin-ChacónMA. Current uses and applications of stereotactic body radiation therapy. Gac Med Mex. 2023;159(3):262-269.

[7] RosenbrockJ, LieserA, Ostermann-myrauJ, et al. Efficacy and Toxicity of Robotic Stereotactic Body Radiotherapy of Lung Metastases in Patients With Oligometastatic Disease. Anticancer Res. 2023;43(9):4125-4131,

[8] StefanovicM, CalvetG, Pérez-MonteroH, et al. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study. Clin Transl Oncol. 2023;25(1):199-206.

[9] LeeYH, KangKM, ChoiHS, et al. 207P A comparison of outcomes of stereotactic body radiotherapy versus metastasectomy in patients with pulmonary metastases. J Thorac Oncol. 2018;13(4, Supplement):S124.

[10] DalyME, BeagenP, MadaniMH. Nonsurgical Therapy for Early-Stage Lung Cancer. Hematol Oncol Clin North Am. 2023;37(3):499-512.

[11] LaesekeP, NgC, FerkoN, et al. Stereotactic body radiation therapy and thermal ablation for treatment of NSCLC: A systematic literature review and meta-analysis. Lung cancer. 2023;182:107259.

[12] KroezeSGC, PavicM, StellamansK, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium. Lancet Oncol. 2023;24(3):e121-e132.

[13] BaumannBC, Bernstein KDA, DeLaneyTF, et al. Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity. J Surg Oncol. 2020;122(5):877-883.

[14] NicosiaL, CucciaF, MazzolaR, et al. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Strahlenther Onkol. 2020;196(9):813-820.

[15] BonomoP, GretoD, DesideriI, et al. Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?Oral Oncol. 2019;93:1-7.

[16] RusthovenKE, Kavanagh BD, BurriSH, et al. Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases. J Clin Oncol. 2009;27(10):1579-1584.

[17] PalmaDA, OlsonR, HarrowS, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051-2058.

[18] WangX, BaiY, VermaV, et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2023;115(6):742-748.

[19] NiibeY, Yamamoto T, OnishiH, et al. Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients. Anticancer Res. 2020;40(1):393-399.

[20] PalmaDA, OlsonR, HarrowS, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET Phase II randomized trial. J Clin Oncol. 2020;38(25):2830-2838.

[21] WujantoC, Vellayappan B, SivaS, et al. Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer. Front Oncol. 2019;9:1219.

[22] AhmedKA, ScottJG, ArringtonJA, et al. Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose. J Thorac Oncol. 2018;13(8):1121-1127.

[23] NicosiaL, Franceschini D, Perrone-CongediF, et al. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study. Radiother Oncol. 2022;166:92-99.

[24] AokiM, Hatayama Y, KawaguchiH, et al. Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study. J Radiat Res. 2016;57(1):55-61.

[25] KalinauskaiteGG, Tinhofer II, KufeldMM, et al. Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases. BMC Cancer. 2020;20(1):404.

[26] ChaiG, YinY, ZhouX, et al. Pulmonary oligometastases treated by stereotactic body radiation therapy (SBRT): a single institution's experience. Transl Lung Cancer Res. 2020;9(4):1496-1506.

[27] OstiMF, AgolliL, ValerianiM, et al. 30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease. Lung Cancer. 2018;122:165-170.

[28] HouX, WangW, ZhangF, Hu K. Stereotactic body radiation therapy for oligometastatic pulmonary tumors from cervical cancer. Asia Pac J Clin Oncol. 2019;15(5):e175-e180.

[29] SchanneDH, Heitmann J, GuckenbergerM, AndratschkeNHJ. Evolution of treatment strategies for oligometastatic NSCLC patients – A systematic review of the literature. Cancer Treat Rev. 2019;80:101892.

[30] GuckenbergerM, Lievens Y, BoumaAB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18-e28.

[31] AminiA, VermaV, SimoneCB, et al. American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2022;112(2):361-375.

[32] KlementRJ, Hoerner-Rieber J, AdebahrS, et al. Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. Radiother Oncol. 2018;127(2):246-252.

[33] SharmaA, DuijmM, Oomen-de HoopE, et al. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy. Acta Oncol. 2019;58(1):74-80.

[34] CheungBMF, LauKS, LeeVHF, et al. Computed tomography-based radiomic model predicts radiological response following stereotactic body radiation therapy in early-stage non-small-cell lung cancer and pulmonary oligo-metastases. Radiat Oncol J. 2021;39(4):254-264.

[35] AvanzoM, Stancanello J, PirroneG, SartorG. Radiomics and deep learning in lung cancer. Strahlenther Onkol. 2020;196(10):879-887.

[36] CillaS, Pistilli D, RomanoC, et al. CT-based radiomics prediction of complete response after stereotactic body radiation therapy for patients with lung metastases. Strahlenther Onkol. 2023;199(7):676-685.

[37] FranceschiniD, De Rose F, FranzeseC, et al. Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019;104(1):111-121.

[38] SharmaA, DuijmM, Oomen-de HoopE, et al. Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy. Acta Oncol. 2018;57(8):1031-1037.

[39] LussierYA, Khodarev NN, ReganK, et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012;7(12):e50141.

[40] UysalE, Aksaray F, DincerS, AltınS. Robotic stereotactic body radiotherapy for recurrent nasopharyngeal carcinoma. Indian J Cancer. 2023;60(3):353-358.

[41] OudinV, Salleron J, MarchesiV, et al. CyberKnife® stereotactic radiation therapy for stage I lung cancer and pulmonary oligometastases: is fiducial implantation still relevant?—a cohort study. J Thorac Dis. 2023;15(9):4636-4647.

[42] HayashiK, SuzukiO, ShiomiH, et al. Stereotactic ablative body radiotherapy with a central high dose using CyberKnife for metastatic lung tumors. BMC Cancer. 2023;23(1):215.

[43] RieberJ, Abbassi-Senger N, AdebahrS, et al. Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. Int J Radiat Oncol Biol Phys. 2017;98(3):511-520.

[44] SivaS, Bressel M, MaiT, et al. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II). JAMA Oncol. 2021;7(10):1476-1485.

[45] van TimmerenJE, EhrbarS, ChamberlainM, et al. Single-isocenter versus multiple-isocenters for multiple lung metastases: Evaluation of lung dose. Radiother Oncol. 2022;166:189-194.

[46] YamamotoT, NiibeY, MatsumotoY, et al. Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors. Anticancer Res. 2020;40(4):2065-2072.

[47] MorenoAC, Fellman B, HobbsBP, et al. Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. J Thorac Oncol. 2020;15(1):101-109.

[48] BurkonP, KazdaT, PospisilP, et al. Ablative dose stereotactic body radiation therapy for oligometastatic disease: a prospective single institution study. Neoplasma. 2019;66(02):315-325.

[49] SomasundaramE, DST, HalimaA, et al. Association between biologically effective dose and local control after stereotactic body radiotherapy for metastatic sarcoma. J Radiosurg SBRT. 2022;8(4):265-273.

[50] AparicioDZ, Requejo OH, de JuliánMÁDL, RodríguezCR, Letón PF. Local control rates in stereotactic body radiotherapy (SBRT) of lung metastases associated with the biologically effective dose. Rep Pract Oncol Radiother. 2019;24(2):142-150.

[51] KlementRJ, Abbasi-Senger N, AdebahrS, et al. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer. 2019;19(1):173.

[52] Chicas-SettR, Morales-Orue I, Castilla-MartinezJ, et al. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review. Int J Mol Sci. 2019;20(9):2173.

[53] Hörner-RieberJ, Bernhardt D, BlanckO, et al. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT. Clin Lung Cancer. 2019;20(6):e667-e677.

[54] KumarA, SalamaJK. Role of radiation in oligometastases and oligoprogression in metastatic non-small cell lung cancer: consensus and controversy. Expert Rev Respir Med. 2023;17(11):1033-1040.

[55] MattesMD, EubankTD, AlmubarakM, et al. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non–Small Cell Lung Cancer. Clin Lung Cancer. 2021;22(4):268-273.

[56] WelshJW, TangC, de GrootP, et al. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019;7(12):1903-1909.

[57] NguyenNP, AliA, Vinh-HungV, et al. Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group. Cancers (Basel). 2022;15(1):244.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.